SEC Form 4 · accession 0001470831-26-000797
Braveheart Bio, Inc. · BRVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jasper Bos
Director
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002131524
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $18.00 | Aug 5, 2026 | A | 30,000 | A | — | Aug 4, 2036 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.